Merck Acquires Chord Therapeutics to Increase Neuroinflammatory Pipeline.

MANews-(C)2009-2021

German science and technology company Merck has agreed to acquire the global rights to develop cladribine, a neuroinflammatory treatment, through the acquisition of Swiss-based biotech company Chord Therapeutics, the company said.

Terms of the transaction were not disclosed. The transaction is expected to be closed in early 2022 after satisfactory completion of customary closing conditions.

Cladribine is used in the treatment of generalised myasthenia gravis and neuromyelitis optica spectrum disorder (NMOSD)...

To continue reading

Request your trial

VLEX uses login cookies to provide you with a better browsing experience. If you click on 'Accept' or continue browsing this site we consider that you accept our cookie policy. ACCEPT